IL-22 Polypeptide Targeting Pancreatic Beta Cells for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes are inadequate in improving insulin production and secretion, leading to significant financial burdens and health issues, with existing therapies failing to effectively address β-cell dysfunction and ER stress, which contributes to insulin resistance and hyperglycemia.
Innovation Solution
Targeting pancreatic β-cells with IL-22 polypeptides conjugated to specific ligands or receptors, such as SUR1, GLP-1R, or GPR40, to directly inhibit oxidative and endoplasmic reticulum stress, thereby enhancing insulin biosynthesis and secretion while reducing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current diabetes therapies are used, then insulin secretion is stimulated, but β-cell dysfunction and ER stress are not effectively addressed
Solution Approach 1:
The patent uses IL-22 as an intermediary molecule that indirectly protects β-cells by reducing ER stress and oxidative stress, rather than directly stimulating insulin secretion. This mediator approach addresses β-cell dysfunction while maintaining insulin production capacity
Solution Approach 2:
The patent changes the therapeutic parameter from direct insulin secretion stimulation to ER stress reduction. By targeting the underlying stress parameters in β-cells, the therapy improves both cell function and insulin secretion capacity simultaneously
2Productivity
If systemic IL-22 administration is used, then metabolic disorders are treated, but off-target effects occur
Solution Approach 1:
The patent segments the therapeutic approach by creating separate targeted delivery systems for different tissues. Instead of systemic administration, distinct conjugates are designed to deliver IL-22 specifically to liver, adipose, or pancreatic tissues, eliminating off-target effects
Solution Approach 2:
The patent applies local quality by providing tissue-specific IL-22 delivery. Each conjugate is designed with properties optimized for its target tissue, ensuring the therapeutic effect is localized where needed without affecting other organs
3Manufacturing precision
If ER stress is reduced in β-cells, then insulin quality and secretion improve, but achieving this selectively is difficult
Solution Approach 1:
The patent uses ligand-conjugate intermediaries that naturally target β-cell receptors. These intermediaries simplify the targeting system by leveraging existing biological recognition mechanisms rather than requiring complex engineered targeting systems
Data Source
Figure 1A~1D
Figure 2A~2E
Figure 3A~3C
AI summary
Disclosed are compositions and methods for modulating oxidative and/or endoplasmic reticulum (OER) stress. More particularly, the present invention discloses compositions and methods that target OER stress inhibitors to pancreatic cells for treating diseases associated with oxidative and/or OER stress, including metabolic disorders such as diabetes.